SCHEMBL1941042

SCHEMBL1941042

Cc1cccc(NC(=O)Nc2cccc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)c2)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.80
EGFR P00533 6/20 0.58
TEK Q02763 6/20 0.58
ERBB2 P04626 5/20 0.58
ERBB3 P21860 5/20 0.58
ERBB4 Q15303 5/20 0.58
NTRK1 P04629 6/20 0.55
NTRK2 Q16620 5/20 0.55
NTRK3 Q16288 3/20 0.55
KDR P35968 5/20 0.54
KCNH2 Q12809 3/20 0.53
AURKA O14965 2/20 0.53
AURKB Q96GD4 2/20 0.53
IKBKE Q14164 1/20 0.53
RET P07949 3/20 0.50
LCK P06239 2/20 0.50
SRC P12931 2/20 0.50
PDPK1 O15530 1/20 0.50
PLK4 O00444 2/20 0.49
MAP4K4 O95819 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942239 0.95 PDGFRB (0.79) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1940924 0.94 PDGFRB (0.85) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1939749 0.93 PDGFRB (0.83) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1940895 0.93 PDGFRB (0.86) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL4078771 0.92 PDGFRB (0.69) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1939484 0.91 PDGFRB (0.73) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1940934 0.91 PDGFRB (0.68) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1939633 0.91 PDGFRB (0.73) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL4086172 0.91 NTRK1 (0.68) PDGFRBEGFRTEKERBB2ERBB3
SCHEMBL1942474 0.91 PDGFRB (0.68) PDGFRBEGFRTEKERBB2ERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP claimed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US claimed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US claimed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 PDGFRB 2465/4885EGFR 2758/4885TEK 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.